SingaporeSG
ChinaCN
MalaysiaMY
IndonesiaID
MyanmarMM
Life Science
- Home
- Products
- Life Science
- Histology
- Confocal Imaging
- PhenoImager™ HT Instrument Automated Quantitative Pathology Imaging System
Confocal Imaging
PhenoImager™ HT Instrument Automated Quantitative Pathology Imaging System
Details
As part of our PhenoImager™ translational solution, multispectral imaging on the PhenoImager HT can be applied across a whole slide using the 6-plex, 7 Color Opal Polaris reagent kit. This enables the biology to be explored at multiple scales, from cell-to-cell interactions to the macroscopic tissue architecture. The whole slide multispectral imaging capability creates a simpler and more robust workflow as fields of view do not need to be selected eliminating selection bias. You also retain a whole slide record, no re-scans required, so that you can easily re-analyze imagery as new understanding emerges. Tissue sections or TMAs can be labeled with immunofluorescent (IF) or immunohistochemical (IHC) stains such as Opal™, or with conventional stains such as H&E and trichrome. When using IF or IHC stains, multiple proteins can be measured on a per tissue, per cell, or per cell compartment (e.g. nuclear, cytoplasmic) basis – even when signals are spectrally similar, are located in the same cellular compartment or are obscured by autofluorescence.
Key Benefits
- State of the art multispectral imaging enables the identification and downstream quantification of multiple overlapping biomarkers (up to 8) without the interference of autofluorescence as the signals are unmixed from one another
- Renowned liquid crystal tunable filter (LCTF) technology generates unmixed, annotated regions of interest of up to 9-colors for deeper interrogation of biology
- Generate unmixed whole slide scans at 40x magnification of up to 7 colors in about 20 minutes (15 x 15 mm region) for analysis of biology across the entire slide in a streamlined workflow and without selection bias
- Fully automated, high-throughput system to accelerate your research and maximize your lab’s resources
- High speed digital whole-slide scanning at 10X-40X in brightfield or fluorescence
- Enclosed system with built-in touchless automation allows you to visualize, analyze, quantify and phenotype immune cells in situ with enhanced security and reliability
- Integrated inForm and phenoptr tissue analysis software packages support configurable projects for biomarker quantification and spatial analysis
| Tissue Formats | Tissue microarrays and tissue sections |
| Multispectral Range | 440 – 780 nm |
| Modality | Brightfield and Fluorescence (multispectral or color) |
| 40x Throughput: Fluorescence (1.5 x 1.5 cm) | 3 digital slides per hour (7 color) |
| 40x Throughput: Brightfield (1.5 x 1.5 cm) | 8 digital slides per hour |
| Automation | Touchless, with walk-away image acquisition |
| Slide capacity | 80 slide capacity with continuous loading technology |
| Multiplexing Capability | Separates up to 9 colors, even if overlapping |
| Image Analysis Software | inForm: intuitive learn-by-example interface to automatically segment and quantitate tissue structures, cells and sub-cellular signatures |
| Resolution | 40x = 0.25 micrometre/pixel 20x = 0.5 micrometre/pixel 10x = 1.0 micrometre/pixel |
| File Format | Akoya Biosciences’ whole slide scan image (.qptiff); Multispectral field format (.iM3); monochrome or color images (JPEG, single-layer TIFF, BMP, or PNG) |
| Automation Compatible | Yes |
| Detection Method | Fluorescence, Brightfield |
| Light Source | LED |
Authors: Kening Li, Yuxin Du, Yun Cai, Wenjie Liu, Yan Lv, Bin Huang, Lishen Zhang, Zhi Wang, Ping Liu, Qian Sun, Ning Li, Mengyan Zhu, Bakwatanisa Bosco, Liangyu Li, Wei Wu, Lingxiang Wu, Jianyong Li, Qianghu Wang, Ming Hong & Sixuan Qian.
Journal: LEUKEMIA
PubMed ID: 35248941
Chemoresistance and relapse are the leading cause of AML-related deaths. Utilizing single-cell RNA sequencing (scRNA-seq), we dissected the cellular states of bone marrow samples from primary refractory or short-term relapsed AML patients and defined the transcriptional intratumoral heterogeneity. We found that compared to proliferating stem/progenitor-like cells (PSPs), a subpopulation of quiescent stem-like cells (QSCs) were involved in the chemoresistance and poor outcomes of AML. By performing longitudinal scRNA-seq analyses, we demonstrated that PSPs were reprogrammed to obtain a QSC-like expression pattern during chemotherapy in refractory AML patients, characterized by the upregulation of CD52 and LGALS1 expression. Flow cytometric analysis further confirmed that the preexisting CD99+CD49d+CD52+Galectin-1+ (QSCs) cells at diagnosis were associated with chemoresistance, and these cells were further enriched in the residual AML cells of refractory patients. Interaction of CD52-SIGLEC10 between QSCs and monocytes may contribute to immune evading and poor outcomes. Furthermore, we identified that LGALS1 was a promising target for chemoresistant AML, and LGALS1 inhibitor could help eliminate QSCs and enhance the chemotherapy in patient-derived primary AML cells, cell lines, and AML xenograft models. Our results will facilitate a better understanding of the AML chemoresistance mechanism and the development of novel therapeutic strategies for relapsed/refractory AML patients.
Authors: Kiyomi Kuba, Hitoshi Inoue, Satoko Matsumura, Yuichiro Enoki, Yasunao Kogashiwa, Yasuhiro Ebihara, Mitsuhiko Nakahira, Tomoko Yamazaki, Masanari Yasuda, Kyoichi Kaira, Hiroshi Kagamu & Masashi Sugasawa.
Journal: Scientific Reports
PubMed ID: 35292878
ivolumab, an immune checkpoint inhibitor is the first-line therapy for platinum-resistant recurrent/metastatic head and neck cancer, and highly effective for some patients. However, no factors have been identified that could predict response or prognosis after nivolumab administration. We retrospectively investigated the association between tumor infiltrating lymphocytes (TILs) of initial pathology and prognosis in patients treated with nivolumab. Twenty-eight patients with human papilloma virus and Epstein–Barr virus unrelated head and neck squamous cell carcinoma were enrolled. CD8+cells, FoxP3+cells and FoxP3-CD4+cells in the tumoral and peritumoral stromal area and PD-L1 were measured. In result, FoxP3-CD4+TIL, FoxP3+TIL, and CD8+TIL were not correlated with survival in either intratumoral and stromal area. In univariate analysis, objective response was significant prognostic factor both in progression-free survival and overall survival (p=0.01, 0.006, respectively). PD-L1 was also significant prognostic factor both in progression-free survival and overall survival (p=0.01, 0.01, respectively). ECOG Performance status was a significant prognostic factor in overall survival (p=0.0009). In the combined analysis of stromal CD8+TIL and PD-L1, PD-L1 positive with high stromal CD8+TIL subgroups had a better prognosis than PD-L1 negative with low stromal CD8+TIL subgroups in progression-free survival (p=0.006). Although these results require a further investigation, PD-L1 and ECOG Performance status and the combination of stromal CD8+TIL and PD-L1 positivity have potential as useful prognostic markers in patients of virus unrelated head and neck squamous cell carcinoma treated with nivolumab.